Recent news highlights MindWalk's continued quarterly losses and revenue challenges, alongside strategic corporate developments.

• MindWalk Holdings Corp. reported a Q4 loss and missed revenue estimates as of July 22, 2026 [N1].
• The company reported a Q3 loss and lagged revenue estimates in March 2026 [N4].
• MindWalk's Q3 2026 earnings call transcript was published in March 2026 [N3].
• The company reported a Q2 loss and lagged revenue estimates in December 2025 [N6].
• MindWalk reported a Q1 loss and missed revenue estimates in September 2025 [N1].

MindWalk has demonstrated revenue growth and improved gross margins in fiscal 2026, reflecting operational progress. Its strategic acquisition of AI-driven multi-omics companies enhances its technological edge in antibody discovery. The company’s investments in R&D and commercialization, including the addition of senior business leadership, support its efforts to expand market presence. The divestiture of non-core assets like IPA Europe provides capital to focus on core growth areas. Strong liquidity ratios as of early 2026 indicate a capacity to fund near-term operations.

Despite revenue growth, MindWalk continues to report significant net losses and has disclosed substantial doubt about its ability to continue as a going concern without additional financing or revenue generation. The company’s operating expenses remain high, with increasing costs in sales, marketing, and administration. The divestiture of IPA Europe reduces operational scale. The company’s reliance on external financing and equity offerings introduces dilution risk. Market competition and execution risks in commercializing novel biotherapeutics and AI platforms may constrain financial performance.

MindWalk's moat is based on its integration of advanced artificial intelligence and multi-omics technologies for antibody discovery and biotherapeutics development, supported by proprietary platforms such as the B cell Select® platform and LensAI™. The acquisition of BioStrand BV and related entities strengthens its technological capabilities and knowledge base. The company's global presence in key life sciences hubs and its standard contractual frameworks with customers provide operational stability. However, the company faces challenges related to sustained profitability and liquidity, which may impact its competitive positioning.

• Liquidity and Going Concern Risk: The company has disclosed substantial doubt about its ability to continue as a going concern without additional financing or sufficient revenue generation.
• Operating Losses: MindWalk has a history of net losses and negative operating cash flows, which may impact its financial stability.
• Dependence on External Financing: The company relies on equity offerings and convertible debentures to fund operations, which may dilute existing shareholders and depend on market conditions.
• Execution Risk: Commercialization of novel AI-driven biotherapeutics and antibody discovery platforms involves technological and market execution risks.
• Geographic and Regulatory Risks: Operations span multiple countries with varying regulatory environments, which may affect business activities and compliance costs.

• MindWalk Holdings Corp. operates globally with offices in Belgium, Canada, and the United States, focusing on antibody discovery and development, including novel biotherapeutics and AI-driven multi-omics technologies.
• The company acquired BioStrand BV and related entities in Belgium in 2022, enhancing capabilities in multi-omics and in silico biotechnology.
• In August 2025, MindWalk sold its IPA Europe business for $12 million USD, generating $10.3 million USD in net proceeds.
• Revenue for fiscal year 2026 was CAD 15.6 million, a 46% increase from CAD 10.6 million in 2025, with gross margin improving to 58.8% from 53.9%.
• The company reported a net loss from continuing operations of CAD 15.1 million in fiscal 2026, an improvement from a loss of CAD 33.1 million in 2025.
• Research and development expenses increased to CAD 4.9 million in 2026 from CAD 4.2 million in 2025, reflecting ongoing investments in the LensAI platform and pipeline assets.
• Sales and marketing expenses rose to CAD 5.9 million in 2026 from CAD 3.6 million in 2025, driven by increased commercialization efforts and the addition of a Chief Business Officer.
• General and administrative expenses increased modestly to CAD 13.2 million in 2026 from CAD 12.1 million in 2025, mainly due to higher salaries and share-based payments.
• As of January 31, 2026, the company held CAD 14.2 million in cash and equivalents, with a current ratio of 3.74 and a cash ratio of 2.82, indicating liquidity.
• The company uses standard Master Services Agreements with customers for antibody and peptide production and is developing standard license agreements for new licensing opportunities.
• Significant revenue sources are from the United States (66%), Europe (18%), and other countries (14%) as of fiscal 2026.
• MindWalk operates leased facilities including a global head office and labs in Victoria, BC, and AI research facilities in Belgium.
• The company has historically incurred net losses and has disclosed substantial doubt about its ability to continue as a going concern without additional financing or revenue generation.
• Convertible debentures were issued in 2024 with terms including conversion rights and registration rights agreements.
• The company sold common shares under at-the-market equity offering facilities in 2024 and 2025, raising proceeds to support operations.